Category: Latest News
-
Oil Drops Below $60 as Peace Hopes and Weak China Data Weigh on Prices
Oil prices slid beneath the $60-a-barrel mark on Tuesday, hitting their lowest levels since May, as optimism around potential Russia-Ukraine peace talks raised expectations that sanctions could eventually be relaxed. Brent crude futures were down $1.03, or about 1.7%, at $59.53 a barrel by 13:40 GMT. U.S. West Texas Intermediate crude also weakened, falling $1.06,…
-
Gold Holds Steady After Jobs Data, Trades Near All-Time Highs
Gold prices were little changed on Tuesday as investors absorbed a wave of U.S. economic releases, looking for signals on the future direction of Federal Reserve interest rate policy. At 09:05 ET (14:05 GMT), spot gold edged up 0.1% to $4,309.57 per ounce, while February gold futures also gained 0.1% to $4,340.50 an ounce. The…
-
Morgan Stanley Sees Compelling Value in Defense Stocks Ahead of 2026
Morgan Stanley believes U.S. defense equities present an attractive opportunity heading into 2026, arguing that current share prices do not adequately capture the outlook for continued expansion in U.S. defense spending, even amid ongoing political uncertainty. In a sector outlook, analyst Kristine Liwag said the bank views the group as undervalued, noting that it “provides…
-
Jumia Shares Jump as Craig-Hallum Starts Coverage With Bullish Outlook
Shares of Jumia Technologies AG (NYSE:JMIA) climbed 8.1% on Tuesday after Craig-Hallum analyst Ryan Sigdahl initiated coverage of the African e-commerce group with a Buy rating and a price target of $18 per share. In his initiation note, Sigdahl pointed to Jumia’s “decade-plus long growth runway” within Africa’s still underpenetrated e-commerce market, arguing that the…
-
Royalty Pharma Shares Edge Higher on Acquisition of Oncology Drug Royalties
Shares of Royalty Pharma plc (NASDAQ:RPRX) gained 2.4% in pre-market trading on Tuesday after the company said it had secured royalty interests linked to two emerging cancer treatments. The firm is acquiring an existing low single-digit royalty on Nuvalent’s oncology drugs neladalkib and zidesamtinib in a transaction valued at up to $315 million. Both therapies…
-
Vital Farms Shares Slide After Company Trims 2025 Revenue Forecast
Shares of Vital Farms Inc. (NASDAQ:VITL) fell 8.1% in pre-market trading on Tuesday after the ethical food producer cut its revenue outlook for fiscal 2025, citing temporary disruptions linked to the rollout of a new ERP system. The company now expects 2025 net revenue to range between $755 million and $765 million, reflecting short-term disruptions…
-
Cementos Pacasmayo Shares Surge on Holcim Deal for Controlling Interest
Shares of Cementos Pacasmayo SAA ADR (NYSE:CPAC) jumped nearly 29% in pre-market trading on Tuesday after the Peruvian cement producer revealed that Holcim has agreed to acquire a majority stake in the company. Under the agreement, the Swiss cement group will purchase Inversiones Aspi S.A., the holding company that owns 50.01% of Cementos Pacasmayo. The…
-
Dragonfly Energy Shares Slide After Reverse Stock Split Plan Revealed
Shares of Dragonfly Energy Holdings Corp. (NASDAQ:DFLI) sank nearly 44% in pre-market trading on Tuesday after the battery technology company announced it will carry out a 1-for-10 reverse stock split in order to remain compliant with Nasdaq listing requirements. The reverse split is scheduled to take effect on December 18, 2025, and will reduce the…
-
Autozi Shares Rally After $980 Million Procurement MOU Announcement
Shares of Autozi Internet Technology (NASDAQ:AZI) surged 39% in pre-market trading on Tuesday after the company revealed it had entered into a Memorandum of Understanding covering potential procurement arrangements valued at roughly $980 million. The non-binding MOU sets out plans for several buyers to leverage Autozi’s digital automotive e-commerce platform for centralized purchasing of complete…
-
Adagene Shares Jump After FDA Awards Fast Track Status to Cancer Treatment
Shares of Adagene Inc. (NASDAQ:ADAG) jumped more than 16% in pre-market trading on Tuesday after the biotech company said the U.S. Food and Drug Administration has granted Fast Track Designation to its cancer therapy muzastotug when used in combination with Merck’s KEYTRUDA. The Fast Track designation covers the treatment of adult patients with microsatellite stable…